CinDome Pharma Announces $40 Million Series B Extension
![](https://cinrx.com/wp-content/uploads/2023/05/cinrx-portfolio-company-cindome-pharma-presents-encouraging-data-on-deudomperidone-cin-102-at-2023-digestive-disease-week-conference-1.jpg)
CinDome Pharma Announces $40 Million Series B Extension
CinDome Pharma announces successful completion of thorough QT study of CIN- 102
![](https://cinrx.com/wp-content/uploads/2023/05/cinrx-portfolio-company-cindome-pharma-presents-encouraging-data-on-deudomperidone-cin-102-at-2023-digestive-disease-week-conference-1.jpg)
CinDome Pharma announced the negative results of a clinical thorough QT/QTc study of CIN-102.
CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102)
![](https://cinrx.com/wp-content/uploads/2023/05/cinrx-portfolio-company-cindome-pharma-presents-encouraging-data-on-deudomperidone-cin-102-at-2023-digestive-disease-week-conference-1.jpg)
CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102).